The 5-hydroxytryptamine receptor 1B (HTR1B), a G protein-coupled receptor, plays a critical role in regulating neurotransmitter release, particularly serotonin, and is implicated in mood, anxiety, and depression. HTR1B antibodies are essential tools for studying this receptor’s expression, localization, and function in neurological and psychiatric research. These antibodies are commonly used in techniques like Western blotting, immunohistochemistry (IHC), and immunocytochemistry (ICC) to detect HTR1B in tissues or cell lines, aiding in understanding its distribution in the central nervous system (e.g., basal ganglia, cortex) and peripheral tissues.
Research using HTR1B antibodies has linked receptor dysfunction to disorders such as depression, obsessive-compulsive disorder, and migraine, as well as responses to antidepressants and triptan medications. Antibodies targeting specific epitopes (e.g., extracellular or intracellular domains) help elucidate HTR1B's signaling pathways and interactions with ligands or drugs.
Validation of HTR1B antibodies includes testing in knockout models or siRNA-treated samples to confirm specificity. Cross-reactivity with related receptors (e.g., HTR1A) must be ruled out. Commercial antibodies vary in host species (rabbit, mouse) and applications, requiring careful selection based on experimental needs. Ongoing studies using these antibodies contribute to drug development and personalized therapies targeting serotonin-related disorders.